Assembly Biosciences Inc (ASMB) : Ecor1 Capital scooped up 844,862 additional shares in Assembly Biosciences Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 2,943,164 shares of Assembly Biosciences Inc which is valued at $17,070,351.Assembly Biosciences Inc makes up approximately 7.36% of Ecor1 Capital’s portfolio.
Other Hedge Funds, Including , Sabby Management added ASMB to its portfolio by purchasing 90,362 company shares during the most recent quarter which is valued at $524,100. Assembly Biosciences Inc makes up approx 0.17% of Sabby Management’s portfolio.Vanguard Group Inc reduced its stake in ASMB by selling 36,760 shares or 7.8% in the most recent quarter. The Hedge Fund company now holds 434,374 shares of ASMB which is valued at $2,519,369. State Board Of Administration Of Florida Retirement System sold out all of its stake in ASMB during the most recent quarter. The investment firm sold 13,328 shares of ASMB which is valued $80,235.Jennison Associates reduced its stake in ASMB by selling 1,963 shares or 0.1% in the most recent quarter. The Hedge Fund company now holds 2,037,542 shares of ASMB which is valued at $12,001,122. Assembly Biosciences Inc makes up approx 0.01% of Jennison Associates’s portfolio.
Assembly Biosciences Inc opened for trading at $6.15 and hit $6.33 on the upside on Thursday, eventually ending the session at $6.25, with a gain of 2.29% or 0.14 points. The heightened volatility saw the trading volume jump to 16,090 shares. Company has a market cap of $108 M.
Assembly Biosciences Inc. (Assembly) is a biopharmaceutical company. The Company is engaged in the development of oral therapies for the cure of intractable infectious diseases focusing on hepatitis B virus (HBV) and clostridium (C.) difficile-associated infections (CDAD). The target of Assembly’s lead program is a clinical cure for HBV for which it is developing a series of compounds known as core protein allosteric modulators (CpAMs). Assembly’s clinical strategy includes testing CpAMs as monotherapy and in combination. Assembly’s CDAD program is -based on the targeted delivery of microbiome-based therapies in an oral formulation applying Assembly’s coating and encapsulation technology that allows for targeted delivery of complex agents to select regions of the gastrointestinal (GI) tract. The Company’s HBV and microbiome therapies are both in pre-clinical development stages.